Paid and unpaid work lost, hidden costs
The hidden costs of impairments in working ability and functional capacity among Finnish patients with inflammatory bowel diseases and rheumatoid arthritis were assessed in a
12.7.2017
RRMS: Considerable differences in the cost effectiveness of treatments
Multiple sclerosis (MS) progression and the cost-effectiveness analysis of first line disease modifying MS treatments (DMT) in Finland ESiOR studied relapsing-remitting MS (RRMS) progression and
24.2.2017
Professor pharmacoeconomics
Janne Martikainen, PhD (health economics), Adjunct Professor (economic evaluation of pharmaceuticals) in Turku University and one of ESiOR’s health economists and partners is now also
3.1.2017
Development project
Development of business and services portfolio Project’s goals are to innovate and develop new business, support business growth and strengthen national and international competitiveness of
21.12.2016
Nordic RWD conference, meet us there
ESiOR Ltd takes part in Nordic conference on Real World Data – Collaboration between pharma industry and Academia on November 29-30, 2016, in Helsinki. We
21.11.2016
New information on atrial fibrillation and anticoagulation
A large proportion of patients with atrial fibrillation (AF) do not attain the treatment targets with traditional warfarin treatment. As a result, they remain at
18.10.2016
New cost effectiveness information on major depressive disorder
Many patients with major depressive disorder (MDD) do not have adequate response to the first medical treatment or have adverse effects that lead to treatment
18.10.2016
Essential ESiOR: 5 presentations at ISPOR
It is time for celebration. ESiOR will participate in International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress in Vienna for the tenth
17.10.2016
Hallinen T, Soini E, et al.
Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients. SpringerPlus 2016;5:1354. Julkaisuluettelo
12.10.2016
ESiOR at Terveys ja talous -päivät
ESiOR participated in Terveys ja talous -päivät (Finnish seminar on health and economics) and presented a new study on cost-effectiveness of atrial fibrillation treatments “Eteisvärinän
12.10.2016
4th Nordic Conference on Research in Patient Safety and Quality in Healthcare
ESiOR Oy participates in the 4th Nordic Conference on Research in Patient Safety and Quality in Healthcare 19th-20th May 2016 in Hotel Puijonsarvi, Kuopio. We will be
18.4.2016
Practice: From cost utility to clinical cost benefit
Most health economists have probably faced a situation where ICER, CEEF, CEAF, EVPI or some other complicated cost-utility analysis outcome do not alone make the
23.3.2016
